Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
|Articles|October 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 10
- Volume 4
- Issue 10
Rose Kushner Award Winners Announced
BETHESDA, Md-The American Medical Writers Association (AMWA) has announced the winners of the 1995 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer, sponsored by the AMWA and Zeneca Pharmaceuticals.
Advertisement
BETHESDA, Md-The American Medical Writers Association (AMWA) hasannounced the winners of the 1995 Rose Kushner Awards for WritingAchievement in the Field of Breast Cancer, sponsored by the AMWAand Zeneca Pharmaceuticals.
- Lay articles: Laurie Tarkan, How Daughters Face Their Mother'sBreast Cancer (McCall's), and Nicole Spelhaug, Breast Cancer:New Perspectives Can Replace Unrealistic Fears (supplement tothe Mayo Clinic Health Letter).
- Scientific articles: Amy S. Langer and Karen Hassey Dow, TheBreast Cancer Advocacy Movement and Nursing (Oncology Nursing).
- Scripts: Jane Glenn Haas, On-Line (The Orange Count News Channel).
- Brochures and monographs: Aaron Rachel Rose, For Single WomenWith Breast Cancer (Y-ME National Breast Cancer Organization).
Articles in this issue
about 31 years ago
New Markers May Help Predict Course of Prostate Carcinomaabout 31 years ago
Needle Exchange Programs Lower HIV Risk: Panelabout 31 years ago
Computerized Database Could Lead to Improved Staging of Lung Cancerabout 31 years ago
Centocor Wellness Program Includes Mobile Mammography Vanabout 31 years ago
Institute of the Future Urges US to Increase Spending on Basic R&Dabout 31 years ago
Yeast-Derived GM-CSF (Leukine) Cleared for Use in Older AML Patientsabout 31 years ago
Spiral CT Offers Better Detection of Disease, More Accurate Stagingabout 31 years ago
New Colon Ca Agent Is Available in FranceAdvertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
4
Managing Dermatologic Toxicity and Holding Therapy
5